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Abstract Investigations determined that the cell matrix-associ-
ated prekallikrein (PK) activator is prolylcarboxypeptidase. PK
activation on human umbilical vein endothelial cell (HUVEC)
matrix is inhibited by antipain (IC50 = 50 WM) but not anti-
factor XIIa antibody, 3 mM benzamidine, 5 mM iodoacetic
acid or iodoacetamide, or 3 mM N-ethylmaleimide. Corn tryp-
sin inhibitor (IC50 = 100 nM) or Fmoc-aminoacylpyrrolidine-2-
nitrile (IC50 = 100 WM) blocks matrix-associated PK activation.
Angiotensin II (IC50 = 100 WM) or bradykinin (IC50 = 3 mM),
but not angiotensin 1^7 or bradykinin 1^5, inhibits matrix-as-
sociated PK activation. ECV304 cell matrix PK activator also
is blocked by 100 WM angiotensin II, 1 WM corn trypsin inhib-
itor, and 50 WM antipain, but not angiotensin 1^7. 1 mM an-
giotensin II or 300 WM Fmoc-aminoacylpyrrolidine-2-nitrile in-
directly blocks plasminogen activation by inhibiting kallikrein
formation for single chain urokinase activation. On immunoblot,
prolylcarboxypeptidase antigen is associated with HUVEC ma-
trix. These studies indicate that prolylcarboxypeptidase is the
matrix PK activator. 5 2002 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Previous investigations have shown that when high molec-
ular weight kininogen (HK) and prekallikrein (PK) assemble
on matrix of human umbilical vein endothelial cells (HUVEC)
or ECV304 cells, PK becomes activated to kallikrein [1]. This
¢nding suggests that the plasma kallikrein/kinin system par-
ticipates in matrix-associated activities such as wound healing,
tissue remodeling, and angiogenesis. PK activation on cell
matrix was inhibited by antipain and corn trypsin inhibitor
(CTI) [1]. The PK activating enzyme on cell matrix is present
when the endothelial cells were grown in factor XII de¢cient
serum, indicating that PK activation is independent of factor
XIIa [1]. Kallikrein formation on extracellular matrix was
essential for single chain urokinase activation and subsequent
plasmin formation [1,2]. The activation and inhibitory pattern
for PK on endothelial cell matrix is similar to that which has
been described for PK on con£uent monolayers of cultured
endothelial cells [2,3]. Recent investigations indicate that the
enzyme prolylcarboxypeptidase (PRCP, lysosomal carboxy-
peptidase, or angiotensinase C) is the endothelial cell PK ac-
tivator that functions independent of factor XIIa [4]. The
present investigations show that PRCP is the PK activator
associated with endothelial cell matrices.
2. Materials and methods
2.1. Materials
Angiotensin II (ATII) and antipain hydrochloride were purchased
from Calbiochem (San Diego, CA, USA). Single chain HK, human
PK, human Glu-plasminogen, CTI, and a neutralizing polyclonal goat
anti-human antibody to human factor XII were purchased from En-
zyme Research Laboratories (South Bend, IN, USA) [4]. Biotinylated
HK was prepared as previously reported [1,2]. Bradykinin (BK), bra-
dykinin 1^5 (BK 1^5) (RPPGF), aprotinin, and angiotensin 1^7 (Ang
1^7) were purchased from Sigma (St. Louis, MO, USA). Prestained
low molecular weight standards, polyacrylamide and nitrocellulose
membrane was obtained from Bio-Rad (Richmond, CA, USA). HU-
VEC, trypsin-EDTA, trypsin neutralizing bu¡er, bovine brain extract,
fetal bovine serum (FBS) and endothelial growth medium (EGM)
were purchased from Clonetics (San Diego, CA, USA). The chemilu-
minescence ECL detection system was obtained from Amersham (Ar-
lington Heights, IL, USA). Triton X-100 was purchased from Boehr-
inger-Mannheim (Indianapolis, IN, USA). Single chain urokinase
plasminogen activator (ScuPA) was obtained from American Diag-
nostica (Greenwich, CT, USA). Peptide Z-Pro-Pro-OH (ZPP-OH)
was purchased from Bachem (King of Prussia, PA, USA). H-D-Pro-
Phe-Arg-paranitroanilide (S2302) and Val-Leu-Lys-paranitroanilide
(S2251) were purchased from Diapharma (Franklin, OH, USA).
Fmoc-aminoacylpyrrolidine-2-nitrile (FMOC), a potent prolyl oligo-
peptidase inhibitor, was generously provided by Dr. Sherwin Wilks,
Mount Sinai Medical School, New York, NY, USA [5]. Rabbit anti-
serum against PRCP was generously provided by Dr. Randal Skidgel,
University of Illinois, Chicago, IL, USA.
2.2. Endothelial cell culture
HUVEC were maintained in EGM supplemented with 2% FBS and
bovine brain extract in an incubator with 5% CO2 at 37‡C. HUVEC
cells from the 1st to 5th passages were cultured on ¢bronectin (2 mg/
ml) coated 96-well plates and used within 24 h. ECV304 cells were
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grown to con£uence on 60 mm dishes in Ham F-12 Nutrient Mixture
medium (Life Technologies, Gaithersburg, MD, USA) supplemented
with 10% heat-inactivated fetal calf serum (Cultilab, Campinas, SP,
Brazil) containing 10 U penicillin and 10 Wg streptomycin/ml (Life
Technologies). In preparation for binding experiments, ECV304 cells
were removed from their culture dishes after incubation for 40 min
with 3.73 mg/ml pancreatin (Sigma) and grown in 96-well microtiter
plates at 37‡C under 2.5% CO2. These cells were used within 24 h of
becoming con£uent.
2.3. Preparation of the extracellular matrix
Con£uent monolayers of HUVEC or ECV304 cells in 96-well mi-
crotiter plate wells were washed with 0.15 M NaCl, 0.01 M sodium
phosphate, pH 7.4 (PBS) and then removed after 15 min treatment
with 0.5% Triton X-100 in PBS [1]. The plate was then incubated with
0.025 M NH4OH for 10 min [1]. The matrix was washed ¢ve times
with 0.02 M Tris^HCl, 0.15 M NaCl, pH 7.4 containing 0.05% Tween
20 followed by washing ¢ve times with HEPES^Tyrode bu¡er
(0.135 M NaCl, 14.7 M HEPES, 2.7 M KCl, 0.36 mM NaH2PO4,
11.9 mM NaHCO3, 3.5 mg/ml dextrose, 2 mM Ca2þ, 1 mM Mg2þ,
3.5 mg/ml bovine serum albumin, pH 7.35). All the incubations were
performed under the same conditions in an incubator with 5% CO2 at
37‡C. In all cases after this treatment, no cells were detected by light
microscopy.
2.4. PK activation on matrix
HUVEC matrix was incubated with 100 Wl of 20 nM HK in
HEPES^Tyrode bu¡er containing 50 WM Zn2þ (binding bu¡er) for
1 h at 37‡C. The HK was removed and then the matrix was incubated
with 100 Wl of 20 nM PK in binding bu¡er for 1 h at 37‡C. The matrix
was washed to remove any unbound PK. Formed kallikrein activity
was determined by the hydrolysis of 100 Wl S2302 (0.8 mM) for 1 h at
37‡C. The hydrolysis of the substrate was measured at 405 nm using a
Microplate auto reader EL 311 (Bio-Tek Instrument, Winooski, VT,
USA). Alternatively, PK activation on ECV304 matrix was measured
by hydrolysis of 0.4 mM S2302 for 2 h at 37‡C in the absence or
presence of inhibitors.
Investigations determined if 300 WM leupeptin, 100 WM antipain,
3 mM N-ethylmaleimide or benzamidine, or 5 mM iodoacetic acid or
iodoacetamide blocked activation of PK on the matrix [4]. Further
investigations determined if PK activation was altered in the presence
of ZPP-OH (1 WM^15 mM), antipain (1 WM^1 mM), CTI (1 nM^2
WM), FMOC (0.1 WM^1 mM), ATII (1 WM^1 mM), Ang 1^7 (1 WM^1
mM), BK (10 WM^5 mM), or BK 1^5 (10 WM^15 mM).
2.5. Plasminogen activation on matrix
Investigations determined if kallikrein-initiated plasminogen activa-
tion was altered by inhibitors of the matrix-associated PK activator
[1,2]. In these experiments, the matrix was incubated with 100 Wl of
20 nM HK in binding bu¡er containing 50 WM Zn2þ for 1 h at 37‡C.
The HK was removed and then the matrix was incubated with 100 Wl
of 20 nM PK in the same bu¡er for 1 h at 37‡C in the absence or
presence of FMOC (300 WM), aprotinin (100 nM), ZPP-OH (15 mM),
Ang 1^7 (1 mM), or ATII (1 mM). The PK was removed by washing
and then the matrix was incubated with 100 Wl of 1 WM Glu-plasmin-
ogen in binding bu¡er containing 50 WM Zn2þ for an additional 1 h at
37‡C in the absence or presence of the same inhibitors. The matrix
was then washed to remove the unbound plasminogen. Plasminogen
activation was initiated by the addition of ScuPA (2 nM) and 0.3 mM
S2251 and hydrolysis of the substrate was measured for 1 h at 405 nm.
2.6. Gel electrophoresis and immunoblot
Microtiter plate cuvette wells covered with HUVEC matrix were
incubated with 15 Wl/well of SDS^PAGE sample bu¡er for 5 min at
37‡C. The solubilized contents of three wells were pooled and applied
on a 10% SDS^PAGE. After electrophoresis, the material was electro-
blotted at 8 mA overnight onto a nitrocellulose membrane. The mem-
brane then was washed three times with 0.01 M Tris, 0.15 M NaCl,
pH 7.4 containing 0.02% Tween 20, followed by blocking with 5%
dried milk in the same bu¡er for 1 h, after which the membrane was
incubated with rabbit antiserum against PRCP diluted 1:2000 in Blot-
to for 1 h at room temperature [1,4]. The membrane was then rinsed
three times for 15 min with bu¡er followed by incubation with a sheep
anti-rabbit IgG (1:500) conjugated with horseradish peroxidase for 1 h
at room temperature. After washing again, the membrane was devel-
oped with the ECL system and the autoradiograph was prepared.
3. Results
Experiments determined if the HUVEC matrix-associated
PK activator was inhibited by the same compounds that
blocked puri¢ed HUVEC PK activator, PRCP [4]. Investiga-
tions determined if the matrix-associated PK activator was
factor XIIa tightly bound and not exchangeable from the
matrix surface. 200 Wg/ml IgG or neutralizing antibody to
human factor XIIa did not inhibit PK activation on HUVEC
matrix (Fig. 1) [4]. 3 mM benzamidine also had no inhibitory
e¡ect on the matrix-associated PK activator. 300 WM leupep-
tin and 100 WM antipain inhibited PK activation on HUVEC
by 70 and 83%, respectively. Alternatively, cysteine protease
inhibitors, 3 mM N-ethylmaleimide, 5 mM iodoacetamide, or
5 mM iodoacetic acid, produced little inhibition of PK acti-
vation on the matrix. Investigations next determined if the
matrix-associated PK activator was blocked by inhibitors pre-
viously characterized to inhibit HUVEC PRCP [4]. Increasing
concentrations of the prolyl oligopeptidase inhibitors ZPP-
OH or FMOC, antipain, or CTI, blocked the matrix-associ-
ated PK activator with an IC50 of 5 mM, 100 WM, 50 WM, or
100 nM, respectively (Fig. 2).
Further experiments determined that speci¢c substrates of
PRCP also inhibited the matrix-associated PK activator (Fig.
3). The peptides ATII or BK, but not Ang 1^7 or BK 1^5,
blocked matrix-associated PK activation with an IC50 of 100
WM or 3 mM, respectively (Fig. 3).
Studies next determined if the ECV304 cell matrix-associ-
ated PK activator was inhibited by the same spectrum of
inhibitors as HUVEC matrix-associated PK activator [1].
ATII at 100 WM, but not Ang 1^7, completely blocked the
PK activator from ECV304 cell matrix (Fig. 4). Likewise,
CTI and antipain at 1 WM and 50 WM blocked ECV304 cell
Fig. 1. The nature of the matrix enzyme that activates PK. HUVEC
matrix was prepared in 96-well microtiter plates as indicated in Sec-
tion 2. After washing in binding bu¡er, the cells were incubated
with 20 nM HK for 1 h, after which the wells were washed and in-
cubated with 20 nM PK in the same bu¡er in the absence or pres-
ence of 200 Wg/ml goat IgG or goat anti-human factor XIIa anti-
body, 300 WM leupeptin, 100 WM antipain, 3 mM N-ethylmaleimide,
5 mM iodoacetamide or iodoacetic acid, or 3 mM benzamidine for
1 h at 37‡C. At the conclusion of the incubation, the wells were
washed and the amount of formed kallikrein was measured by hy-
drolysis of 0.8 mM S2302. The results presented are the meanRS.D.
of three independent experiments.
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matrix-associated PK activator 80% and 100%, respectively
(Fig. 4).
Since kallikrein is a kinetically favorable activator of Scu-
PA, investigations determined if inhibition of the HUVEC
matrix-associated PK activator would block plasminogen ac-
Fig. 2. Speci¢c inhibitors of the matrix-associated PK activating en-
zyme. HUVEC matrix was prepared and, after incubation with
20 nM HK as described in Fig. 1, the wells were washed and incu-
bated with 20 nM PK in the absence or presence of 1 WM^15 mM
ZPP-OH, 1 WM^1 mM antipain, 1 nM^2 WM CTI, or 0.01 WM^1
mM FMOC for 1 h at 37‡C. At the conclusion of the incubation,
the wells were washed and the amount of formed kallikrein was
measured by hydrolysis of 0.8 mM S2302. The results presented are
the meanRS.D. of three independent experiments.
Fig. 3. Substrate inhibitors of the matrix-associated PK activating
enzyme. HUVEC matrix was prepared and after incubation with
20 nM HK as described in Fig. 1, the wells were washed and incu-
bated with 20 nM PK in the same bu¡er in the absence or presence
of 1 WM^1 mM ATII, 10 WM^5 mM BK, 1 WM^1 mM Ang 1^7, or
10 WM^15 mM BK 1^5 for 1 h at 37‡C. At the conclusion of the
incubation, the wells were washed and the amount of formed kalli-
krein was measured by hydrolysis of 0.8 mM S2302. The results
presented are the meanRS.D. of three independent experiments.
Fig. 4. Inhibition of ECV304 cell matrix-associated PK activating
enzyme. ECV304 cell matrix was prepared in 96-well microtiter
plates as indicated in Section 2. After washing, the cells were incu-
bated with 20 nM HK for 1 h, after which the wells were washed
and incubated with 20 nM PK in the same bu¡er in the absence or
presence of ATII, Ang 1^7, CTI, or antipain at the indicated con-
centrations for 1 h at 37‡C. At the conclusion of the incubation,
the wells were washed and the amount of formed kallikrein was
measured by hydrolysis of 0.4 mM S2302. The results presented are
the meanRS.D. of three independent experiments.
Fig. 5. Inhibition of plasmin formation on HUVEC matrix by inhi-
bition of PK activation. HUVEC matrix was prepared and incuba-
ted with 20 nM HK as described in Fig. 1, after which the wells
were washed and incubated with 20 nM PK in the same bu¡er for
another 1 h in the absence or presence of 1 mM ATII, 1 mM Ang
1^7, 15 mM ZPP-OH, 100 nM aprotinin, or 300 WM FMOC. At
the conclusion of this incubation, the wells were washed and incu-
bated with 1 WM Glu-plasminogen in the absence or presence of the
same inhibitors for 1 h at 37‡C. At the conclusion of the incuba-
tion, the wells were washed and the amount of formed plasmin was
measured by hydrolysis of added 0.3 mM S2251 in the presence of
2 nM ScuPA. The results presented are the meanRS.D. of three in-
dependent experiments.
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tivation [1,2,5]. 1 mM ATII, but not Ang 1^7, inhibited 90%
of plasmin formation (Fig. 5). Likewise, 100 nM aprotinin, 15
mM ZPP-OH, or 300 WM FMOC blocked greater than 70%
of plasminogen activation on HUVEC matrix (Fig. 5).
Lastly, experiments determined if there is immunochemical
evidence for matrix-associated PRCP. Solubilized HUVEC
matrix on immunoblot expressed human PRCP antigen
(Fig. 6).
4. Discussion
The combined studies indicate that the HUVEC and
ECV304 matrix-associated PK activator is a protease with
the same inhibitory features of that described for the PK
activator isolated from endothelial cells [4]. The ¢nding that
antipain and leupeptin block the activator, but that N-ethyl-
maleimide, iodoacetamide, or iodoacetic acid does not, sug-
gests that it is not cysteine protease. The fact that this acti-
vator is inhibited by ATII, FMOC, or ZPP-OH suggests that
it is PRCP. ATII with a penultimate proline produces sub-
strate inhibition of PRCP when present in high concentration
because it competes with PK for available enzyme. It is also of
interest that BK is a weak substrate inhibitor of PRCP. Since
BK’s proline is in position 7, the carboxy-terminal arginine in
position 9 must have been removed ¢rst by another carboxy-
peptidase associated with the matrix. Although to our knowl-
edge no carboxypeptidase has been reported to be associated
with endothelial cell matrix, the serine protease deamidase
and the metalloproteases carboxypeptidases M and N are
candidate enzymes to concurrently cleave the C-terminal argi-
nine of BK to allow for des-Arg9-BK to be a substrate inhib-
itor of PRCP [6]. The presence of PRCP antigen associated
with HUVEC con¢rms that the PK activator is this enzyme.
The possibility that the matrices-associated PK activator is
not factor XIIa tightly bound and not exchangeable is shown
by the fact that neither benzamidine nor a neutralizing anti-
body to factor XIIa blocked PK activation on the matrix
[1,4]. CTI blocks the matrix-associated PK activator, but pre-
vious studies show that this inhibitor also blocks PRCP in
addition to its ability to inhibit factor XIIa [4].
The ¢nding that an enzyme originating in a lysosome is
associated with cell matrix is interesting. Recent investigations
in cell biology describe the lysosomes of cells as part of the
endomembrane compartment that directly communicates with
cell membranes to express its constituents [7]. The presence of
the PK activator, PRCP, on cell matrix may be important for
cellular ¢brinolysis. Kinetically favorable activation of single
chain urokinase is mediated by plasma kallikrein [2,8,9]. For-
mation of two chain urokinase with subsequent plasmin for-
mation participates in multiple biologic processes such as cell
migration and proliferation, tissue remodeling and angiogen-
esis, and cell growth and wound healing [10,11]. Liberated BK
from HK by formed kallikrein also stimulates NO formation
and cell proliferation by up-regulating mitogen-activated pro-
tein kinase [2,12,13]. Lastly, the residual cleaved form of HK,
HKa, has the properties to be anti-angiogenic and anti-pro-
liferative, limiting the extent of cell growth and remodeling
[14,15]. Localization and activation of the proteins of the
plasma kallikrein/kinin system on cell matrix indicates new
activities of this system in vascular biology.
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Fig. 6. An immunoblot of matrix-associated PRCP. HUVEC matrix
was solubilized by SDS^PAGE sample bu¡er as indicated in Section
2. The solubilized material was electrophoresed on SDS^PAGE and
electroblotted onto nitrocellulose. After blocking the ¢lter, the mem-
brane was incubated with a primary rabbit antibody to human
PRCP followed by a secondary anti-rabbit antibody conjugated
with horseradish peroxidase. The immunoblot was developed by
chemiluminescence.
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